Midday Report: ENDRA Life (NDRA) Shares Climb for August 5

Equities Staff  |

ENDRA Life Sciences Inc (NASDAQ: NDRA) has climbed $0.03 (10.00%) and sits at $0.33, as of 12:03:05 est on August 5.

224,582 shares have been traded today.

The Company rose 14.81% over the last 5 days and shares advanced 30.42% over the last 30 days.

ENDRA Life is set to release earnings on 2022-08-15.

For technical charts, analysis, and more on ENDRA Life visit the company profile.

About ENDRA Life Sciences Inc

ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS® is designed to work in concert with the over 1 million ultrasound systems in use globally today. TAEUS® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including visualization of tissue temperature during energy-based surgical procedures.

To get more information on ENDRA Life Sciences Inc and to follow the company's latest updates, you can visit the company's profile page here: ENDRA Life Sciences Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content